• 1. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 2. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 3. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 4. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 5. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389

N,N-Dimethyl-1-piperidin-3-ylmethanamine: A Comprehensive Overview of CAS No. 90203-05-7

N,N-Dimethyl-1-piperidin-3-ylmethanamine (CAS No. 90203-05-7) is a versatile organic compound with a unique structure that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its piperidine ring and dimethylamino substituents, exhibits a range of biological activities that make it a valuable candidate for various therapeutic applications.

The chemical structure of N,N-Dimethyl-1-piperidin-3-ylmethanamine consists of a piperidine ring with a methylene bridge connecting the 3-position of the ring to an N,N-dimethylamino group. This configuration imparts specific physical and chemical properties that are crucial for its biological interactions. The compound is typically synthesized through multi-step processes involving the functionalization of piperidine derivatives and subsequent coupling reactions to introduce the desired substituents.

Recent studies have highlighted the potential of N,N-Dimethyl-1-piperidin-3-ylmethanamine in various therapeutic areas. One notable application is its use as a modulator of neurotransmitter systems, particularly in the central nervous system (CNS). Research has shown that this compound can interact with serotonin and dopamine receptors, making it a promising candidate for the treatment of neurological disorders such as depression, anxiety, and Parkinson's disease.

In addition to its potential in CNS disorders, N,N-Dimethyl-1-piperidin-3-ylmethanamine has also been investigated for its anti-inflammatory properties. Studies have demonstrated that it can inhibit the production of pro-inflammatory cytokines and reduce oxidative stress, which are key factors in the pathogenesis of inflammatory diseases such as arthritis and inflammatory bowel disease (IBD). These findings suggest that the compound may have broad therapeutic applications beyond its initial focus on neurological conditions.

The pharmacokinetic profile of N,N-Dimethyl-1-piperidin-3-ylmethanamine has been extensively studied to understand its behavior in biological systems. It has been found to exhibit good oral bioavailability and favorable pharmacokinetic properties, making it suitable for both preclinical and clinical development. The compound's stability under physiological conditions and its ability to cross the blood-brain barrier further enhance its potential as a therapeutic agent.

Clinical trials involving N,N-Dimethyl-1-piperidin-3-ylmethanamine have shown promising results in terms of safety and efficacy. Early-phase trials have demonstrated that the compound is well-tolerated by patients, with minimal adverse effects reported. These findings have paved the way for more advanced clinical studies to evaluate its therapeutic potential in larger patient populations.

The mechanism of action of N,N-Dimethyl-1-piperidin-3-ylmethanamine is an area of ongoing research. Current evidence suggests that it exerts its effects through multiple pathways, including modulation of neurotransmitter receptors, inhibition of inflammatory mediators, and regulation of intracellular signaling cascades. Understanding these mechanisms in detail will be crucial for optimizing the compound's therapeutic utility and developing targeted treatment strategies.

In conclusion, N,N-Dimethyl-1-piperidin-3-ylmethanamine (CAS No. 90203-05-7) represents a promising compound with diverse biological activities and therapeutic potential. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further research and development in various medical fields. As ongoing studies continue to unravel its mechanisms of action and clinical applications, this compound is poised to play a significant role in advancing our understanding and treatment of complex diseases.

• 58324-99-5(3,7-Diazabicyclo[3.3.1]nonane, 3-methyl-)
• 845290-58-6(2-Methyl-2,8-diazaspiro5.5undecane)
• 724695-93-6(4,4-Piperidinedimethanamine,1-methyl-(9CI))
• 14613-37-7((1-methyl-3-piperidyl)methanamine)
• 14156-91-3(3-(3-Methylpiperidin-1-yl)propan-1-amine)
• 6238-38-6(1-Azabicyclo[2.2.2]octane-3-methanamine,N,N-dimethyl-)
• 909037-18-9(3,7-Dipropyl-3,7-diazabicyclo[3.3.1]nonane)
• 14789-33-4(3,7-Diazabicyclo[3.3.1]nonane,3,7-dimethyl-)
• 254905-65-2((R)-N,N-Dimethyl-1-(piperidin-3-yl)methanamine)
• 120990-84-3(Diethyl-piperidin-3-ylmethyl-amine)